Thomas E Hutson

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects
    Thomas E Hutson
    Experimental Therapeutics Program, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cancer Res 9:1354-60. 2003
  2. ncbi request reprint Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma
    Saby George
    Experimental Therapeutics Program, Department of Hematology and Medical Oncology R33, The Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave, Cleveland, OH, 44195, USA
    Cancer Chemother Pharmacol 62:347-54. 2008
  3. doi request reprint Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer 116:5383-90. 2010
  4. ncbi request reprint Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma
    Gheath Alatrash
    Experimental Therapeutics Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Clin Oncol 22:2891-900. 2004
  5. doi request reprint Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Brian I Rini
    Cleveland Clinic Taussig Cancer Institute, Main Campus, Euclid Avenue, Cleveland, OH 44195, USA
    Lancet 378:1931-9. 2011
  6. ncbi request reprint Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity
    Ena Segota
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 41950, USA
    Urol Oncol 25:46-52. 2007
  7. doi request reprint Sunitinib rechallenge in metastatic renal cell carcinoma patients
    Ivan N Zama
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer 116:5400-6. 2010
  8. ncbi request reprint Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma
    Thomas E Hutson
    Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation
    Invest New Drugs 22:277-84. 2004
  9. doi request reprint Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
  10. doi request reprint Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Cancer 117:752-7. 2011

Detail Information

Publications37

  1. ncbi request reprint Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects
    Thomas E Hutson
    Experimental Therapeutics Program, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cancer Res 9:1354-60. 2003
    ..The purpose of our study was to determine the maximum tolerated dose (MTD), dose-limiting toxicities, and effects on chemokine/cytokine gene expression in peripheral blood mononuclear cells (PBMCs) of consensus IFN (CIFN)...
  2. ncbi request reprint Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma
    Saby George
    Experimental Therapeutics Program, Department of Hematology and Medical Oncology R33, The Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave, Cleveland, OH, 44195, USA
    Cancer Chemother Pharmacol 62:347-54. 2008
    ..To determine the maximal tolerable dose (MTD) and preliminary efficacy of concurrent subcutaneous (SC) administration of PEG-Intron and rIL-2 in patients with metastatic renal cell carcinoma (RCC)...
  3. doi request reprint Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer 116:5383-90. 2010
    ..Despite common use, the safety and activity of sorafenib in bevacizumab- or sunitinib-refractory mRCC have not been prospectively investigated...
  4. ncbi request reprint Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma
    Gheath Alatrash
    Experimental Therapeutics Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Clin Oncol 22:2891-900. 2004
    ....
  5. doi request reprint Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Brian I Rini
    Cleveland Clinic Taussig Cancer Institute, Main Campus, Euclid Avenue, Cleveland, OH 44195, USA
    Lancet 378:1931-9. 2011
    ....
  6. ncbi request reprint Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity
    Ena Segota
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 41950, USA
    Urol Oncol 25:46-52. 2007
    ....
  7. doi request reprint Sunitinib rechallenge in metastatic renal cell carcinoma patients
    Ivan N Zama
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer 116:5400-6. 2010
    ....
  8. ncbi request reprint Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma
    Thomas E Hutson
    Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation
    Invest New Drugs 22:277-84. 2004
    ..The in vivo clinical activity of this combination has not been fully evaluated...
  9. doi request reprint Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    ..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response...
  10. doi request reprint Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Cancer 117:752-7. 2011
    ..Gemcitabine is a nucleoside analogue with broad antitumor activity. In a phase 2 study of combined docetaxel and gemcitabine, the authors assessed its safety and activity in patients with chemotherapy-naive, metastatic CRPC...
  11. ncbi request reprint Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
    Tarek Mekhail
    Experimental Therapeutics Department, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer 97:170-8. 2003
    ....
  12. ncbi request reprint Rapid analysis of docetaxel in human plasma by tandem mass spectrometry with on-line sample extraction
    Adrian G Grozav
    Department of Chemistry, Cleveland State University, 2399 Euclid Avenue, Cleveland, OH 44115, USA
    J Pharm Biomed Anal 36:125-31. 2004
    ..3%), and excellent intra-assay (0.6-3.8%) and inter-assay (2.0-5.7%) precision. Its applicability to clinical samples was demonstrated by measuring patient plasma samples after treatment of weekly docetaxel at 25 mg/m2 as 60-min infusion...
  13. ncbi request reprint Problems with the randomized discontinuation design
    Guru Sonpavde
    J Clin Oncol 24:4669-70; author reply 4670-1. 2006
  14. ncbi request reprint Axitinib for renal cell carcinoma
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology PA, Houston, TX 77598, USA
    Expert Opin Investig Drugs 17:741-8. 2008
    ..Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor...
  15. doi request reprint Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
    ..We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy...
  16. ncbi request reprint Evolving role of novel targeted agents in renal cell carcinoma
    Thomas E Hutson
    Baylor Sammons Cancer Center, U S Oncology Research Network Dallas, Texas, USA
    Oncology (Williston Park) 21:1175-80; discussion 1184, 1187, 1190. 2007
    ..Recently reported and ongoing clinical trials will help further define the role of these agents as therapy for metastatic RCC...
  17. ncbi request reprint Renal cell cancer
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, and US Oncology Research Network, Dallas, Texas, USA
    Cancer J 13:282-6. 2007
    ..Recently reported and planned clinical trials will help clarify the role of these agents. The future of therapy for renal cancer appears promising owing to the efficacy of these novel agents...
  18. ncbi request reprint New approaches in hormone refractory prostate cancer
    Guru Sonpavde
    U S Oncology Research Network, Houston, TX, USA
    Am J Clin Oncol 29:196-201. 2006
    ....
  19. doi request reprint Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:1552-8. 2008
    ..On the basis of outcome data from that trial, the authors developed a nomogram for predicting the probability of 12-month progression-free survival for patients who received sunitinib therapy...
  20. ncbi request reprint A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma
    Thomas E Hutson
    Baylor Charles A Sammons Cancer Center Texas Oncology, PA, Dallas, 75246, USA
    Clin Genitourin Cancer 4:296-8. 2006
  21. ncbi request reprint Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Genitourin Cancer 5:S31-9. 2006
    ..Combinations of these agents are being evaluated. Clinical trials designed to further assess these and other agents need to be vigorously supported...
  22. ncbi request reprint Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Charles A Sammons Cancer Center, Dallas, TX 75254, USA
    Clin Genitourin Cancer 4:181-6. 2005
    ..Until results from ongoing trials clearly demonstrate superiority of newer agents over IFN-alpha or IL-2, these agents should remain a standard of care for the treatment of RCC...
  23. ncbi request reprint Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 356:115-24. 2007
    ..Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted...
  24. ncbi request reprint Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel
    Ronald J Halbert
    Cerner Life Sciences, Beverley Hills, California, USA
    Cancer 107:2375-83. 2006
    ..The authors convened a panel of medical and urologic oncologists to rate the appropriateness of the main options...
  25. doi request reprint Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium
    Thomas E Hutson
    US Oncology Research, Inc, Genitourinary Oncology Program, Houston, TX, USA
    Invest New Drugs 26:151-8. 2008
    ..However, the safety and efficacy of P combined with GC therapy is unknown. This phase I trial was designed to determine the maximum tolerated dose (MTD) of GC followed by P+G in patients with metastatic TCC...
  26. ncbi request reprint Hormone refractory prostate cancer: Management and advances
    Guru Sonpavde
    US Oncology Research Network Houston, TX, USA
    Cancer Treat Rev 32:90-100. 2006
    ....
  27. ncbi request reprint Evolving role of pegylated interferons in metastatic renal cell carcinoma
    Toni K Choueiri
    Department of Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    Expert Rev Anticancer Ther 3:823-9. 2003
    ..Studies evaluating these agents in the treatment of metastatic renal cell carcinoma and other cancers are ongoing...
  28. ncbi request reprint Renal cell carcinoma: what does the future hold?
    Thomas E Hutson
    Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    BJU Int 102:5-6. 2008
  29. doi request reprint Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology, PA, US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Opin Investig Drugs 17:253-61. 2008
    ..Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor against VEGFR-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-alpha, PDGFR-beta and c-kit...
  30. ncbi request reprint Current optimal chemotherapy for advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research and Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Rev Anticancer Ther 8:51-61. 2008
    ..The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances...
  31. ncbi request reprint Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  32. ncbi request reprint Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview
    Thomas E Hutson
    Baylor University Medical Center, GU Oncology Program, Texas Oncology, PA, Sammons Cancer Center, 3535 Worth Street, Dallas TX 75246, USA
    Expert Rev Anticancer Ther 7:1193-202. 2007
    ..Targeted agents offer an alternative for patients with advanced renal cell carcinoma, as initial therapy or after failure of cytokine treatment...
  33. ncbi request reprint Pazopanib: a novel multitargeted tyrosine kinase inhibitor
    Guru Sonpavde
    Texas Oncology, P A, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Curr Oncol Rep 9:115-9. 2007
    ..Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies...
  34. ncbi request reprint Management of recurrent testicular germ cell tumors
    Guru Sonpavde
    US Oncology Research, Houston, Texas, USA
    Oncologist 12:51-61. 2007
    ..Salvage surgical resection has an important role in selected patients. Cisplatin-refractory patients have a poor prognosis with current therapy, and novel chemotherapeutic and biologic agents need to be discovered for such patients...
  35. ncbi request reprint Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
    ..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma...
  36. ncbi request reprint Systemic chemotherapy for urothelial cancer
    Guru Sonpavde
    Texas Oncology, PA, Webster, TX 77598, USA
    Clin Genitourin Cancer 5:34-42. 2006
    ..With the unraveling of bladder cancer biology and the discovery of novel agents targeting several carcinogenic pathways, the future of therapy for transitional cell carcinoma appears promising...
  37. ncbi request reprint Recent advances in the therapy of renal cancer
    Guru Sonpavde
    US Oncology Research, Houston, Texas, USA
    Expert Opin Biol Ther 7:233-42. 2007
    ..The future of the therapy of renal cancer appears promising owing to the efficacy of these novel agents. Clinical trials designed to further assess these and other agents need to be vigorously supported...